STOCK TITAN

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Pacira BioSciences joins ASA's Industry Supporter Program to improve patient care and reduce reliance on opioids.
Positive
  • Pacira BioSciences has joined ASA's Industry Supporter Program to collaborate with the anesthesiology community and advance education and innovation. They will provide valuable educational resources to improve patient care and support ASA's major events.
Negative
  • None.

SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA’s Industry Supporter Program to support the Society’s more than 56,000 physician anesthesiologist members to improve patient care and reduce reliance on opioids for the treatment of postsurgical or chronic pain.

“We are delighted to establish this collaboration with Pacira, which we believe represents an excellent opportunity to advance education and innovation for our members,” said ASA President Michael Champeau, M.D., FAAP, FASA. “Pacira and the ASA share a mutual commitment toward best-in-class pain medicine and optimizing patient outcomes, and we look forward to working together to advance these shared goals.”

As an Industry Supporter, Pacira is helping to establish a strong, mutually beneficial relationship with the anesthesiology community, strengthen collaboration between physician anesthesiologists and industry, and add to the value the Society provides to patients and the public, while providing invaluable year-round support of ASA programs and priorities related to non-opioid alternatives and postsurgical care.

Through the program, Pacira is supporting ASA’s major events, including this year’s ANESTHESIOLOGY® annual meeting, with valuable educational resources to improve patient care.

“Pacira is pleased to support ASA and we look forward to collaborating in our efforts to improve patient outcomes through opioid-minimizing strategies,” said Dave Stack, CEO and Chairman of Pacira. “Our organizations share a common interest in advancing education and innovation for the anesthesia community and the patients we serve. We believe that working together, Pacira and the ASA can effect significant change in the best interest of patients.”

Launched in 2010, ASA’s Industry Supporter Program is limited to 10 organizations at any time. Participation is intended for companies who want to stand apart by showcasing high-level commitment to the education of physician anesthesiologists, the anesthesia care team and advancement of the specialty.

About the American Society of Anesthesiologists

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research, and scientific professional society with more than 56,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during, and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about how physician anesthesiologists help ensure patient safety, visit www.asahq.org/MadeforThisMoment. Like ASA on Facebook, follow ASALifeline on Twitter.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) has three commercial-stage products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. Pacira is also developing other innovative products to address debilitating conditions such as cardiac electrical storm, atrial fibrillation, chronic pain, and spasticity. To learn more about Pacira, visit www.pacira.com.


FAQ

What is the purpose of Pacira BioSciences joining ASA's Industry Supporter Program?

To improve patient care and reduce reliance on opioids.

What will Pacira BioSciences provide as an Industry Supporter?

Valuable educational resources to improve patient care and support ASA's major events.

What is the goal of the collaboration between Pacira BioSciences and ASA?

To advance education and innovation for the anesthesia community and improve patient outcomes.

How many organizations can participate in ASA's Industry Supporter Program at a time?

10 organizations.

When was ASA's Industry Supporter Program launched?

In 2010.

Pacira BioSciences, Inc.

NASDAQ:PCRX

PCRX Rankings

PCRX Latest News

PCRX Stock Data

1.25B
46.02M
1.21%
108.08%
8.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TAMPA

About PCRX

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.